What is the share price of IPCA Laboratories Ltd (IPCALAB) today?
The share price of IPCALAB as on 24th July 2026 is ₹1762.70. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on IPCA Laboratories Ltd (IPCALAB) share?
The past returns of IPCA Laboratories Ltd (IPCALAB) share are- Past 1 week: -6.75%
- Past 1 month: 8.42%
- Past 3 months: 13.29%
- Past 6 months: 21.16%
- Past 1 year: 14.40%
- Past 3 years: 122.42%
- Past 5 years: 58.38%
What are the peers or stocks similar to IPCA Laboratories Ltd (IPCALAB)?
The peers or stocks similar to IPCA Laboratories Ltd (IPCALAB) include:What is the market cap of IPCA Laboratories Ltd (IPCALAB) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of IPCA Laboratories Ltd (IPCALAB) is ₹44720.44 Cr as of 24th July 2026.What is the 52 week high and low of IPCA Laboratories Ltd (IPCALAB) share?
The 52-week high of IPCA Laboratories Ltd (IPCALAB) is ₹1944.90 and the 52-week low is ₹1251.60.What is the PE and PB ratio of IPCA Laboratories Ltd (IPCALAB) stock?
The P/E (price-to-earnings) ratio of IPCA Laboratories Ltd (IPCALAB) is 39.19. The P/B (price-to-book) ratio is 4.70.Which sector does IPCA Laboratories Ltd (IPCALAB) belong to?
IPCA Laboratories Ltd (IPCALAB) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy IPCA Laboratories Ltd (IPCALAB) shares?
You can directly buy IPCA Laboratories Ltd (IPCALAB) shares on Tickertape. Simply sign up, connect your demat account and place your order.
IPCA Laboratories Ltd
IPCALAB Share Price
NSE₹1,762.700.48% (-8.50)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
IPCALAB Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
IPCALAB Performance & Key Metrics
IPCALAB Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 39.19 | 4.70 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 44.74 | 5.90 | 0.53% |
88%
Analysts have suggested that investors can buy this stock
from 17 analysts
Price Upside
Earnings Growth
Rev. Growth
IPCALAB Company Profile
Ipca Laboratories Limited is engaged in pharmaceuticals business. The Company is a manufacturer and supplier of over 10 active pharmaceutical ingredients (APIs).
SUNPHARMA
PE Ratio
40.57
40.57
1Y Return
14.72%
14.72%
Buy Reco %
93.75
93.75
TORNTPHARM
PE Ratio
87.23
87.23
1Y Return
40.96%
40.96%
Buy Reco %
78.57
78.57
CIPLA
PE Ratio
29.38
29.38
1Y Return
5.20%
5.20%
Buy Reco %
66.67
66.67
ZYDUSLIFE
PE Ratio
21.94
21.94
1Y Return
14.15%
14.15%
Buy Reco %
55.17
55.17
LUPIN
PE Ratio
20.32
20.32
1Y Return
22.10%
22.10%
Buy Reco %
55.56
55.56
IPCALAB Sentiment Analysis
IPCALAB Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
IPCALAB Stock Summary · June 2026
Management framed the quarter as a combination of solid top‑line growth and improving profitability, with domestic formulations at about INR 853 crore in Q4 and consolidated FY26 EBITDA margin at roughly 20.72%, above the company’s 20% target. They emphasised a disciplined, division‑level strategy that prioritises 2–3 power brands, a controlled cadence of roughly 18–20 domestic launches a year expected to add about 1–2% to domestic growth, and targeted annual price increases near 5–6%, while actively passing API cost hikes through to buyers. Management acknowledged material‑cost inflation (roughly 10–12%) and sharply higher freight and logistics costs (about +25%), which have lengthened transit times and will create a short‑term profitability drag such as in Q1 despite tight working‑capital control and elevated inventories in parts of the group. Integration actions at the acquired business—including India production shifts and elimination of overseas overheads—are expected to drive a margin recovery toward roughly 12–13% and near‑term growth, while incremental R&D and tech‑transfer spending supports institutional U.S. programs.
IPCALAB Stock Growth Drivers
IPCALAB Stock Growth Drivers
5Broad-based Revenue Momentum across Markets and Segments
The company delivered sustained top-line growth across domestic, export and U.S. channels, evidencing diversified momentum.
Material Margin Expansion and Profitability Outperformance
Profitability improved meaningfully with both standalone and consolidated EBITDA margins expanding and exceeding guidance. Standalone
IPCALAB Stock Challenges
IPCALAB Stock Challenges
8Sharp Decline in Institutional Sales
The institutional segment has contracted materially, with institutional sales falling roughly 24% for the year
Substantial Input-Cost Inflation from Supply-Chain Disruptions
Ongoing supply-chain disturbances and petroleum-linked pressures have driven broad input-cost inflation of roughly 10%–12%, with
IPCALAB Forecast
IPCALAB Forecasts
Price
Revenue
Earnings
IPCALAB Share Price Forecast
IPCALAB Share Price Forecast
2026
Current
₹1,762.70
Baseline
Forecast for Jul 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
2026
Current
₹1,762.70
Baseline
Forecast for Jul 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
IPCALAB Company Revenue Forecast
IPCALAB Company Revenue Forecast
2026
Current
₹9.84
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
2026
Current
₹9.84
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
IPCALAB Stock EPS (Earnings Per Share) Forecast
IPCALAB Stock EPS (Earnings Per Share) Forecast
2026
Current
₹44.98
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
2026
Current
₹44.98
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
IPCALAB
IPCALAB
Income
Balance Sheet
Cash Flow
Quarterly Normal View
IPCALAB Income Statement
IPCALAB Income Statement
Quarterly Normal View
| Quarter | dec 2023 | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | mar 2026 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 2,143.76 | 2,051.95 | 2,113.24 | 2,381.16 | 2,265.48 | 2,272.51 | 2,341.51 | 2,584.36 | 2,430.34 | 2,482.22 | ||||||||||
Operating & Other expenses | 1,721.97 | 1,847.85 | 1,699.91 | 1,913.42 | 1,782.29 | 2,022.88 | 1,892.43 | 2,069.84 | 1,859.15 | 1,950.43 | ||||||||||
EBITDA | 421.79 | 204.10 | 413.33 | 467.74 | 483.19 | 249.63 | 449.08 | 514.52 | 571.19 | 531.79 | ||||||||||
| Depreciation/Amortization | 99.50 | 98.13 | 98.89 | 100.35 | 98.46 | 100.12 | 100.06 | 103.33 | 107.59 | 107.14 | ||||||||||
| PBIT | 322.29 | 105.97 | 314.44 | 367.39 | 384.73 | 149.51 | 349.02 | 411.19 | 463.60 | 424.65 | ||||||||||
| Interest & Other Items | 33.40 | 29.37 | 24.05 | 22.56 | 16.81 | 21.51 | 18.51 | 19.61 | 17.62 | 20.20 | ||||||||||
| PBT | 288.89 | 76.60 | 290.39 | 344.83 | 367.92 | 128.00 | 330.51 | 391.58 | 445.98 | 404.45 | ||||||||||
| Taxes & Other Items | 109.01 | 17.01 | 98.15 | 115.35 | 119.78 | 60.18 | 97.30 | 109.01 | 119.71 | 105.38 | ||||||||||
| Net Income | 179.88 | 59.59 | 192.24 | 229.48 | 248.14 | 67.82 | 233.21 | 282.57 | 326.27 | 299.07 | ||||||||||
| EPS | 7.09 | 2.35 | 7.58 | 9.05 | 9.78 | 2.67 | 9.19 | 11.14 | 12.86 | 13.31 |
IPCALAB Company Updates
IPCALAB Stock Peers
IPCALAB Past Performance & Peer Comparison
IPCALAB Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| IPCA Laboratories Ltd | 39.19 | 4.70 | — |
| Sun Pharmaceutical Industries Ltd | 40.57 | 5.55 | 0.82% |
| Torrent Pharmaceuticals Ltd | 87.23 | 10.73 | 0.68% |
| Cipla Ltd | 29.38 | 3.30 | 0.92% |
IPCALAB Stock Price Comparison
Compare IPCALAB with any stock or ETFCompare IPCALAB with any stock or ETF
IPCALAB
IPCALAB Holdings
IPCALAB Shareholdings
IPCALAB Promoter Holdings Trend
IPCALAB Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
IPCALAB Institutional Holdings Trend
IPCALAB Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
IPCALAB Shareholding Pattern
IPCALAB Shareholding Pattern
IPCALAB Shareholding History
IPCALAB Shareholding History
Foreign Institutions
Mutual Funds Invested in IPCALAB
Mutual Funds Invested in IPCALAB
No mutual funds holding trends are available
Top 5 Mutual Funds holding IPCA Laboratories Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 6.8833% | Percentage of the fund’s portfolio invested in the stock 3.05% | Change in the portfolio weight of the stock over the last 3 months -0.32% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 7/80 (-1) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 4.4980% | Percentage of the fund’s portfolio invested in the stock 3.11% | Change in the portfolio weight of the stock over the last 3 months -0.35% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 2/71 (+1) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.5235% | Percentage of the fund’s portfolio invested in the stock 2.02% | Change in the portfolio weight of the stock over the last 3 months -0.09% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 7/99 (-2) |
Compare 3-month MF holding change on Screener
smallcases containing IPCALAB stock
smallcases containing IPCALAB stock
A smallcase is a basket of stocks/ETFs that represents an idea or theme.Diversify your risk and buy smallcases that have IPCA Laboratories Ltd
IPCALAB Events
IPCALAB Events
IPCALAB Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
IPCALAB Dividend Trend
No dividend trend available
IPCALAB Upcoming Dividends
IPCALAB Upcoming Dividends
No upcoming dividends are available
IPCALAB Past Dividends
IPCALAB Past Dividends
Cash Dividend
Ex DateEx DateAug 5, 2025
Final
Final | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Aug 5, 2025
Cash Dividend
Ex DateEx DateNov 27, 2024
Interim
Interim | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Nov 27, 2024
Cash Dividend
Ex DateEx DateAug 6, 2024
Final
Final | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Aug 6, 2024
Cash Dividend
Ex DateEx DateNov 22, 2023
Interim
Interim | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Nov 22, 2023
Cash Dividend
Ex DateEx DateNov 22, 2022
Interim
Interim | Div/Share: ₹4.00
Dividend/Share
₹4.00
Ex DateEx Date
Nov 22, 2022
IPCALAB Stock News & Opinions
IPCALAB Stock News & Opinions
Articles & Videos
Spotlight
Spotlight
Ipca Laboratories Ltd gains for fifth sessionIpca Laboratories Ltd is up for a fifth straight session in a row. The stock is quoting at Rs 1879.3, up 2.11% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.45% on the day, quoting at 24160.1. The Sensex is at 77455.4, up 0.52%. Ipca Laboratories Ltd has risen around 21.23% in last one month. Meanwhile, Nifty Pharma index of which Ipca Laboratories Ltd is a constituent, has risen around 7.92% in last one month and is currently quoting at 25907.1, up 0.64% on the day. The volume in the stock stood at 1.72 lakh shares today, compared to the daily average of 2.43 lakh shares in last one month.The PE of the stock is 40.42 based on TTM earnings ending March 26.Powered by Capital Market - Live
1 week agoCapital Market - Live
Corporate
Corporate
Ipca Laboratories to hold AGMIpca Laboratories announced that the Annual General Meeting(AGM) of the company will be held on 13 August 2026.
1 week agoCapital Market - Live
Spotlight
Spotlight
Ipca Laboratories Ltd spurts 2.44%Ipca Laboratories Ltd is up for a third straight session in a row. The stock is quoting at Rs 1831.5, up 2.44% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.04% on the day, quoting at 24216.7. The Sensex is at 77693.16, up 0.16%. Ipca Laboratories Ltd has risen around 16.23% in last one month. Meanwhile, Nifty Pharma index of which Ipca Laboratories Ltd is a constituent, has risen around 5.67% in last one month and is currently quoting at 25674.1, down 0.32% on the day. The volume in the stock stood at 2.25 lakh shares today, compared to the daily average of 2.31 lakh shares in last one month.The PE of the stock is 39.27 based on TTM earnings ending March 26.Powered by Capital Market - Live
1 week agoCapital Market - Live
Corporate
Corporate
Ipca Laboratories board approves scheme of amalgamationThe board of Ipca Laboratories at its meeting held on 26 June 2026 has approved the scheme of amalgamation of Krebs Biochemicals & Industries (Transferor Company) with the company (Transferee Company) under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013.
4 weeks agoCapital Market - Live
Spotlight
Spotlight
Ipca Laboratories Ltd spurts 0.16%, up for fifth straight sessionIpca Laboratories Ltd is up for a fifth straight session today. The stock is quoting at Rs 1627.6, up 0.16% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.7% on the day, quoting at 23991.35. The Sensex is at 76862.12, up 0.87%. Ipca Laboratories Ltd has gained around 3.6% in last one month. Meanwhile, Nifty Pharma index of which Ipca Laboratories Ltd is a constituent, has gained around 1.73% in last one month and is currently quoting at 24989.95, up 0.45% on the day. The volume in the stock stood at 51017 shares today, compared to the daily average of 2.5 lakh shares in last one month.The PE of the stock is 35.66 based on TTM earnings ending March 26.Powered by Capital Market - Live
1 month agoCapital Market - Live
Spotlight
Spotlight
Ipca Laboratories Ltd eases for fifth straight sessionIpca Laboratories Ltd dropped for a fifth straight session today. The stock is quoting at Rs 1575.6, down 0.47% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 1.17% on the day, quoting at 23899.05. The Sensex is at 76440.61, up 1.21%.Ipca Laboratories Ltd has eased around 4.29% in last one month.Meanwhile, Nifty Pharma index of which Ipca Laboratories Ltd is a constituent, has eased around 2.12% in last one month and is currently quoting at 24380.05, down 0.58% on the day. The volume in the stock stood at 77999 shares today, compared to the daily average of 3.04 lakh shares in last one month.The PE of the stock is 34.84 based on TTM earnings ending March 26.Powered by Capital Market - Live
1 month agoCapital Market - Live
Spotlight
Spotlight
Ipca Laboratories Ltd soars 0.79%, rises for fifth straight sessionIpca Laboratories Ltd gained for a fifth straight session today. The stock is quoting at Rs 1654.8, up 0.79% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.55% on the day, quoting at 23237.85. The Sensex is at 73854.65, down 0.52%. Ipca Laboratories Ltd has risen around 7.8% in last one month. Meanwhile, Nifty Pharma index of which Ipca Laboratories Ltd is a constituent, has risen around 0.72% in last one month and is currently quoting at 24248.05, up 0.4% on the day. The volume in the stock stood at 6.88 lakh shares today, compared to the daily average of 3.84 lakh shares in last one month.The PE of the stock is 36.1 based on TTM earnings ending March 26.Powered by Capital Market - Live
1 month agoCapital Market - Live
Spotlight
Spotlight
Ipca Laboratories Ltd gains for third straight sessionIpca Laboratories Ltd gained for a third straight session today. The stock is quoting at Rs 1598.7, up 2.83% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.03% on the day, quoting at 23399. The Sensex is at 74300.47, down 0.06%. Ipca Laboratories Ltd has gained around 3.69% in last one month. Meanwhile, Nifty Pharma index of which Ipca Laboratories Ltd is a constituent, has gained around 2.67% in last one month and is currently quoting at 24086.6, up 0.46% on the day. The volume in the stock stood at 1.69 lakh shares today, compared to the daily average of 3.54 lakh shares in last one month.The PE of the stock is 34.14 based on TTM earnings ending March 26.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Corporate
Board of Ipca Laboratories recommends final dividendIpca Laboratories announced that the Board of Directors of the Company at its meeting held on 29 May 2026, inter alia, have recommended the final dividend of Rs 6 per equity Share (i.e. 600%) , subject to the approval of the shareholders.
1 month agoCapital Market - Live
Earnings
Earnings
Ipca Laboratories consolidated net profit rises 340.98% in the March 2026 quarterNet profit of Ipca Laboratories rose 340.98% to Rs 299.07 crore in the quarter ended March 2026 as against Rs 67.82 crore during the previous quarter ended March 2025. Sales rose 6.31% to Rs 2388.48 crore in the quarter ended March 2026 as against Rs 2246.69 crore during the previous quarter ended March 2025. For the full year,net profit rose 54.69% to Rs 1141.12 crore in the year ended March 2026 as against Rs 737.68 crore during the previous year ended March 2025. Sales rose 7.91% to Rs 9646.33 crore in the year ended March 2026 as against Rs 8939.59 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales2388.482246.69 6 9646.338939.59 8 OPM %20.2619.09 -20.5119.31 - PBDT557.41433.17 29 2077.071734.01 20 PBT450.27333.05 35 1658.951336.19 24 NP299.0767.82 341 1141.12737.68 55 Powered by Capital Market - Live
1 month agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 12.4%, vs industry avg of 12.48%
Over the last 5 years, market share decreased from 1.94% to 1.92%
Over the last 5 years, net income has grown at a yearly rate of 0.02%, vs industry avg of 10.55%